文献速递淋巴瘤造血干细胞移植与细胞治疗

PD-1抑制剂联合方案用于自体移植前可改善经典型霍奇金淋巴瘤结局

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.
PubMed 文献 · Blood · 2026-01-01

该多中心回顾性研究纳入2010至2022年在6家移植中心接受ASCT的1280例R/R cHL患者,25%在ASCT前接受过PD-1抑制剂,2年PFS显著优于BV组和单纯化疗组。ASCT前PD-1阻断是独立预后因素。

要点

  • ASCT前使用PD-1抑制剂者2年PFS达88.2%,显著优于BV组的70.2%和单纯化疗组的67.4%。
  • 在ASCT前达完全缓解的患者中,PD-1抑制剂的获益仍然显著。
  • 拟行ASCT的R/R cHL患者应考虑以PD-1为基础的挽救治疗。

核心结论

  • ASCT前接受PD-1阻断与更优的移植后结局独立相关。
  • 拟行ASCT的R/R cHL患者应接受以PD-1为基础的挽救治疗。

研究设计与样本

  • 多中心回顾性研究,纳入2010至2022年在6家移植中心接受ASCT的1280例R/R cHL患者。
  • 所有患者均未在初治阶段接受PD-1阻断治疗。
  • 25%在ASCT前接受PD-1抑制剂,其中10%与化疗联用;28%接受不含PD-1阻断的BV挽救治疗;其余接受单纯挽救化疗。

主要发现

  • ASCT前任何时点使用PD-1抑制剂者2年PFS为88.2%,BV组为70.2%,单纯化疗组为67.4%(P< .0001)。
  • 在ASCT前达完全缓解的患者中,PD-1阻断的获益仍然显著。

临床怎么用

  • 对拟行ASCT的R/R cHL患者,优先考虑含PD-1抑制剂的挽救方案。
  • ASCT前应评估PD-1抑制剂的使用时机及与化疗的联合策略。

局限性

  • 回顾性设计,存在选择偏倚可能。
  • PD-1抑制剂使用方案与化疗联用比例不一,异质性较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Previous retrospective studies have suggested benefit for PD-1 blockade before autologous stem cell transplant (ASCT) but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti-PD-1 based salvage on outcomes for patients with R/R cHL, we retrospectively reviewed 1280 patients with R/R cHL who underwent ASCT from 2010 to 2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. Overall, 25% received a PD-1 inhibitor at any point before ASCT (10% in conjunction with chemotherapy), 28% received salvage brentuximab vedotin (BV) without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year progression-free survival than those who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, and 67.4%, respectively; P< .0001). When restricted to patients in complete response before ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade before ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1-based salvage.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Desai SH, Moskowitz AJ, Merryman RW, et al. PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma. Blood. 2026. PMID: 41405496. doi:10.1182/blood.2025030151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。